LISATA THERAPEUTICS, INC. — Director's Dealing 2017

Jan 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2017-01-09

Reporting Person: TRABER PETER G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-09	Common Stock	A	1650	—	Acquired	4300	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-09	Options to Purchase Common Stock	$3.54	A	2750	Acquired	2027-01-09	Common Stock (2750)	Direct

Footnotes

F1: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018.

F2: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans.